Showing results (461-470 of 1,962) with videos related to

Sort By:
Pageof 197
Expert Opinion on Drug Discovery|May 10, 2024
Another string to your bow: machine learning prediction of the pharmacokinetic properties of small moleculesDavide Bassani, Neil John Parrott, Nenad Manevski, et al.
Expert Opinion on Drug Discovery|December 25, 2023
Designing drugs optimized for both blood-brain barrier permeation and intra-cerebral partitionMaria Dichiara, Giuseppe Cosentino, Giorgia Giordano, et al.
Expert Opinion on Drug Discovery|December 18, 2023
The problem of antimalarial resistance and its implications for drug discoveryThomas Martin Schäfer, Lais Pessanha de Carvalho, Juliana Inoue, et al.
Expert Opinion on Drug Discovery|December 19, 2023
Ultra-high-throughput mass spectrometry in drug discovery: fundamentals and recent advancesJon D Williams, Fan Pu, James W Sawicki, et al.
Expert Opinion on Drug Discovery|October 1, 2019
What are the challenges in commercial non-tuberculous mycobacteria (NTM) drug discovery and how should we move forward?Graham S Timmins
Expert Opinion on Drug Discovery|September 23, 2021
Success stories of AI in drug discovery - where do things stand?Kit-Kay Mak, Madhu Katyayani Balijepalli, Mallikarjuna Rao Pichika
Expert Opinion on Drug Discovery|March 29, 2021
Artificial intelligence in drug discovery: recent advances and future perspectivesJosé Jiménez-Luna, Francesca Grisoni, Nils Weskamp, et al.
Expert Opinion on Drug Discovery|November 12, 2013
High-throughput screening and structure-based approaches to hit discovery: is there a clear winner?Harren Jhoti, Stephen Rees, Roberto Solari
Expert Opinion on Drug Discovery|July 4, 2026
Toward a nuanced framework for the Medical development of ibogaine and its analogues and derivatives: implications for psychopharmacologyChristopher D Verrico, Lynnette A Averill, Cameron J Moore, et al.
Expert Opinion on Drug Discovery|August 14, 2026
A network-driven antiviral discovery pipeline for emerging RNA viruses: a critical perspective from the Red Mexicana de Desarrollo de Antivirales (RMDA)Luis Adrián De Jesús-González, Alan Orlando Santos-Mena, Carlos Noé Farfán-Morales, et al.
Pageof 197